Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3003159 47 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The most effective means of preventing seasonal influenza is through vaccination. In this systematic review, we investigated the efficacy, effectiveness and safety of MF59® adjuvanted trivalent and quadrivalent influenza vaccines to prevent laboratory-confirmed influenza. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials and non-randomised studies of interventions (NRSIs) were eligible for inclusion. The search returned 28,846 records, of which 48 studies on MF59® adjuvanted vaccines met our inclusion criteria. No efficacy trials were identified. In terms of vaccine effectiveness (VE), MF59® adjuvanted trivalent influenza vaccines were effective in preventing laboratory-confirmed influenza in older adults (aged ≥65 years) compared with no vaccination (VE = 45%, 95% confidence interval (CI) 23%–61%, 5 NRSIs across 3 influenza seasons). By subtype, significant effect was found for influenza A(H1N1) (VE = 61%, 95% CI 44%–73%) and B (VE = 29%, 95% CI 5%–46%), but not for A(H3N2). In terms of relative VE, there was no significant difference comparing MF59® adjuvanted trivalent vaccines with either non-adjuvanted trivalent or quadrivalent vaccines. Compared with traditional trivalent influenza vaccines, MF59® adjuvanted trivalent influenza vaccines were associated with a greater number of local adverse events (RR = 1.90, 95% CI 1.50–2.39) and systemic reactions (RR = 1.18, 95% CI 1.02–1.38). In conclusion, MF59® adjuvanted trivalent influenza vaccines were found to be more effective than ‘no vaccination’. Based on limited data, there was no significant difference comparing the effectiveness of MF59® adjuvanted vaccines with their non-adjuvanted counterparts. © 2022 John Wiley & Sons Ltd.
Έτος δημοσίευσης:
2022
Συγγραφείς:
O Murchu, E.
Comber, L.
Jordan, K.
Hawkshaw, S.
Marshall, L.
O’Neill, M.
Ryan, M.
Teljeur, C.
Carnahan, A.
Pérez, J.J.
Robertson, A.H.
Johansen, K.
Jonge, J.D.
Krause, T.
Nicolay, N.
Nohynek, H.
Pavlopoulou, I.
Pebody, R.
Penttinen, P.
Soler-Soneira, M.
Wichmann, O.
Harrington, P.
Περιοδικό:
Reviews in Medical Virology
Εκδότης:
John Wiley and Sons Ltd
Επίσημο URL (Εκδότης):
DOI:
10.1002/rmv.2329
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.